



IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Volume: 8 Issue: VII Month of publication: July 2020

DOI: http://doi.org/10.22214/ijraset.2020.7020

www.ijraset.com

Call: 🕥 08813907089 🔰 E-mail ID: ijraset@gmail.com



A Review on Menorrhagia: Investigation, Miracle Role of Herbs and Medical Treatment

Mr. Sanjit Das¹, Ms. Shashi Daksh², Dr. Aziz Ahmed³, Dr. Kaushal Chandrul⁴

^{1, 2, 3, 4}Department of Pharmacy, Faculty of Pharmaceutical Sciences, Mewar University Chittaurgarh, India

Abstract: At some point in her life, one-third of all women experience heavy menstrual bleeding. Approximately 5 percent of reproductive-age women in Western countries will seek treatment for menorrhagia annually. Half of all women treating for hypermenorrhea have a uterine abnormality, most commonly fibroids (in patients under the age of 40) and endometrial polyps (over the age of 40 years). Suitable Co-Treatment for consider improves quality of life of the patients, to have the best care choices, it is important to make a thorough evaluation of the patient. This guideline provides instructions on how fertile-age women who have menorrhagia can be examined and treated. The subject's own appraisal of the amount of menstrual blood loss generally does not reflect the true amount.

Both patients will undergo a pelvic examination and a vaginal sonography should be done as the most appropriate supplementary test if the menstrual cycle has significantly changed or if anemia is present. Combined with endometrial biopsy, vaginal sonography is a successful method of diagnosing endometrial hyperplasia or carcinoma, but the diagnosis of endometrial polyps and fibroids is insufficient; these can be more reliably diagnosed by sonohysterography or hysteroscopy. Non-steroidal anti-inflammatory drugs and tranexamic acid lower menstrual blood loss by 20 60 percent, and the efficacy of an intrauterine hormonal system (IUS) is comparable to that of endometrial ablation or hysterectomy. Cyclic progesters do not significantly reduce menstrual bleeding in ovulating females.

One of the drug treatments, i.e. the IUS, tranexamic acid, anti-inflammatory medications, or oral contraceptive, will start therapy.

With an effective training and feedback program, diagnosis, medical treatment and monitoring of heavy menstrual bleeding can be arranged in primary health care or in outpatient clinics, reducing the pressure on specialist health service. Keywords: menorrhagia causes, investigation, diagnosis, herbal treatment, synthetic and surgical treatment.

I. INTRODUCTION

The Menarche is a trademark in adolescence from childhood to puberty. The word "menorrhagia" expresses excessive blood loss menstrual bleeding during the period of women. It is a condition affecting the physical, social, emotional or material quality of life of 20-30% reproductive women up to 50 years of age[¹]. Average blood loss during menstruation is about 30 to 40 milliliters; a period of 4-5 days of menorrhagia is a loss of more than 80 milliliters of blood in one cycle, or twice the normal loss of the amount. It may flow longer than 67 days at one time.

Menorrhagia is limiting normal activity and two-thirds of women, and may be anemia due to more blood loss due to menstrual bleeding there may be disorders of prostaglandin associated with idiopathic menorrhagia and abnormally severe bleeding due to fibroids or the use of intrauterine devices $(IUD)[^2]$. Fibroids examined by the National Institute for Health and Care Excellence (NICE) were found in 10% of women with menorrhagia and 40 % of women with severe menorrhagia. But half of women with menorrhagia hysterectomy have a normal uterus [³].

Menorrhagia affects about 53 in 1000 women in India. Recently, the World Health Organization (WHO) reported that 18 million women between the ages of 30 and 35 perceive, but now most women between 20 and 30 are affected globally. Despite the fact great majority of women consult with gynecologists and this condition have not basically pathology or abnormality, there are many women are prepared to subject themselves to potent medical or surgical intervention.[⁴]

The aim of this review article of the literature is to discuss opinion in the investigation and role of herbal and allopathic treatment of menorrhagia. This review concerns the cure of menstrual heavy pain bleeding cycle for which no fundamental cause has been identified (more than 50 percent of cases); this is therefore based on the review article on how we can cure this heavy menstrual bleeding and the treatment aspects of herbal medicines and allopathic medicines affecting and side effects.[^{4]}



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429 Volume 8 Issue VII July 2020- Available at www.ijraset.com

II. SYMPTOMS

The 'abnormal menstrual bleeding 'a normal healthy woman mensuration occurs every 28 days, sometime having a period considered in 21-35 days. In normal case mensuration cycle is about 5 days.

The bleeding may loss more than 80 ml, that's excessive loss it can be detect some symptoms of menorrhagia if you have the following below;

- A. Soaking through that menstrual flow, use more sanitary pads .
- B. The need double sanitary protection for do not fall on clothes .
- C. The menstrual cycle or period that lasts more than 7 days.
- D. The menstrual bleeding includes large blood clots.
- *E.* The daily activities restricting due to heavy pain menstrual flow and uncomfortable life style.
- *F.* May be lead to anemia; like pallor, tiredness, fatigue, shortness of breath. [⁵]

III. MENORRHAGIA CAUSES

There is a balance between the oestrogen and progesterone in a normal menstrual cycle. These are hormones in the body that help to regulate endometrial build-up (uterine inner lining), which is shed during menstruation each month. [6]

There may be an imbalance in levels of oestrogen and progesterone for menorrhagia. The endometrium develops excessively as a result of the unbalance. The heavy menstrual bleeding eventually occurs when it is shed. As hormone imbalances are often seen in menopause-approximating adolescents and women, this type of menorrhagia is fairly common in these groups.

The uterine fibroids (growths) are another common cause of menorrhagia. Other causes might include:

- 1) *Hormonal Disturbances:* If the normal fluctuations of progesterone and estrogen change, the endometrium or uterine inner lining may build up too much. During the menstrual bleeding this is then shed.
- 2) Ovarian Dysfunction: No progesterone is released if the ovary does not release an egg, resulting in a hormone imbalance.
- 3) Uterine Fibroids: Non-cancerous, or benign, tumors
- 4) Uterine Polyps: These benign growths can lead to increased levels of hormones.
- 5) Adenomyosis: endometrial glands become embedded in uterine muscle.
- 6) Intrauterine Non-hormonal Device (IUD): This type of birth control device can lead to more severe bleeding than normal.
- 7) Pelvic Inflammatory Disease (PID): A reproductive organ infection that may have severe complications
- 8) *Complications of Pregnancy:* Examples include a miscarriage or an ectopic pregnancy.
- 9) *Cancer:* The reproductive system is affected by uterine, cervical, and ovarian cancers
- 10) Bleeding Disorders Inherited: These include Von Will brand disease or platelet function disorder.
- 11) Medicines: Anti-inflammatory and anticoagulant medicines can cause severe bleeding.

Other health conditions likely to trigger menorrhagia include thyroid disorders. [⁷]

IV. COMPLICATIONS

- A. Excessive menstrual bleeding can greatly affect your health and quality of life. The considerable blood loss may lead to anemia. Anemia is a condition where the red blood cells that carry oxygen are absent from your blood. Without blood rich in oxygen, you may feel faint and tired.
- *B.* Excessive menstrual bleeding may also be a symptom of some reproductive cancers and fertility-affected conditions. It's important to get medical attention when women excessive bleeding. $[^7]$

V. INVESTIGATION OF MENORRHAGIA

Clinical History: Symptoms associated with a patient with menorrhagia can often be more obvious than laboratory tests. Taking a detailed history of the patient is imperative, given the lengthy list of possible etiologies that contribute to menorrhagia. Requests to be included are as follows;

- A. Exclusion of pregnancy
- *B.* Quantity and quality of bleeding
- C. Patient age



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429 Volume 8 Issue VII July 2020- Available at www.ijraset.com

- D. Pelvic pain and pathology
- E. Menses pattern
- *F.* Sexual activity
- G. Contractive use(hormones or intrauterine device)
- H. Galactorrhea (pituitary tumor)
- I. Presence of hirsutism (polycystic ovarian syndrome)
- J. Systemic illnesses (hepatic/ renal failure or diabetes)
- K. Symptoms of thyroid dysfunction
- L. Excessive bruising or know bleeding disorders.
- *M*. Current medications. [⁸]

VI. DIAGNOSIS OF MENORRHAGIA:

- 1) Laboratory Test: It should be tests patients' full blood count taken to exclude significant anemia and classified hemoglobin less than 10 mg/dL. Including Follicle Stimulating Hormone (FSH), Luteinising Hormone (LH). [⁹]
- 2) *Ultrasound* : to check the event of abnormal findings , imaging modalities by Transadominal and transvaginal , and then check the thickness of follicular phase range from 4 -16mm and endometrial thickness 10 mm grather than 15mm.
- *3)* Endometrial Biopsy and Hysteroscopy: the examination of endometrial cavity, lower segment and cervical canal. Biopsy is the diagnostic test of intrauterine pathology when at 45 age.
- 4) Thyroid Function Test: General examination.
- 5) Pelvic Examination: Uterine size, shape, and contour cervical motion tenderness Adnexal tenderness or masses. [¹⁰]

VII. SYNTHETIC DRUG TREATMENT

Menorrhagia specific therapy is based on a number of factors including:

- 1) Your general history of health and medicine.
- 2) Why and how severe the condition.
- 3) Your tolerance to specific medicines, procedures or treatments.
- 4) The probability of your periods getting less heavy soon.
- 5) Your future plans on childbearing.
- *6)* Condition impacts on your lifestyle.
- 7) Your personal opinion or preferences. [¹¹]

A. Nonsteroidal Anti-inflammatory Drugs

The first-line medical therapy in ovulatory menorrhagia is the non-steroidal anti-inflammatory drugs (NSAIDs). Studies show an average reduction in menstrual blood flow of 20-46 per cent. [12] NSAIDs reduce levels of prostaglandin by inhibiting cyclooxygenase and decreasing the prostacyclin to thromboxane ratios. NSAIDs are ingested over the entire cycle for only 5 days, limiting their most common adverse effect of stomach upset. [13]

B. Oral Contraceptive Pills

Oral contraceptive pills (OCPs) for women who want contraception are a popular first-line therapy. Menstrual blood loss is reduced as effectively as NSAID's secondary to endometrial atrophy. [¹⁴] The OCPs suppress the release of pituitary gonadotropin to prevent ovulation. Common adverse effects in some individuals include breast tenderness, pervasive bleeding, nausea, and possibly related weight gain. A long-term combination of oral estradiol valerate and dienogest in the treatment of women with heavy menstrual bleeding was found to be highly effective when compared with placebo. The oral contraceptive approved by FDA in march 2012, dianogest/estradiol valerate (Natazia), it for heavy menstrual bleeding. [¹⁵]

C. Progestin Therapy

The most frequently prescribed drug for menorrhagia is progestin. When used alone, treatment with this drug results in a significant reduction in menstrual blood flow. Progestin works as an anti-estrogen by minimizing the effects of estrogen on target cells, thus keeping the endometrium in a down-regulated state. Common adverse reactions include weight gain, headaches, edema and depression. $[^{16}]$



International Journal for Research in Applied Science & Engineering Technology (IJRASET) ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429 Volume 8 Issue VII July 2020- Available at www.ijraset.com

D. Levonorgestrel Intrauterine System

The intrauterine levonorgestrel system reduces menstrual blood loss by as much as 97 percent $[1^7]$. It is comparable to the endometrial transcervical resection for menstrual bleeding reduction $[1^{18}]$. Adverse effects include uterine bleeding or spotting, headache, ovarian cysts, vaginitis, dysmenorrhea and breast tenderness.

E. Gonadotropin-releasing Hormone Agonists

Because of high costs and severe adverse effects these agents are used on a short term basis. GnRH agonists are effective in reducing blood flow through the menstruation. They inhibit the release of pituitary FSH and LH, resulting in hypogonadism. A prolonged hypo estrogenic state leads to demineralization of the bone and reduction of cholesterol in the high density lipoprotein (HDL). [19]

F. Danazol

Danazol competes with androgen and progesterone at receptor level and causes amenorrhea within 4-6 weeks. Androgenic effects result in acne, lower breast size and, rarely, lower voice. [²⁰]

G. Conjugated Estrogens

Those agents are administered intravenously in patients with acute bleeding every 4 hours. If no response is noted within 24 hours a D&C procedure may be necessary. When menses slow, follow up with 7 days of estrogen-progestin therapy. That is followed by 3 months of OCPs. $[^{21}]$

H. Tranexamic Acid

Tranexamic acid (Lysteda) was the first no hormonal product approved by the FDA (in November of 2009) for the treatment of heavy menstrual bleeding. It is a synthetic derivative of lysine that uses antifibrinolytic effects by inhibiting the activation of plasminogen to plasmin.

Tranexamic acid's mechanism of action in treating heavy menstrual bleeding is by prevention of fibrinolysis and the breakdown of clots via inhibiting endometrial plasminogen activator.

In a double-blind, placebo-controlled study, women taking 3.9 g/d of tranexamic acid showed a significant reduction in menstrual blood loss and an increase in their health-related quality of life compared with those taking placebo. [38] Common adverse effects include menstrual discomfort, headache, and back pain.

A Cochrane study reviewed data from a non-randomized study that found value in combining desmopressin and tranexamic acid; however, these results need further study. [²²]

VIII. HERBAL TREATMENT

The herbal supplements traditionally used vriouses disorders, hormonal imbalance, infitions etc; It can treat menorrhagia, goals of alternative therapies, and the knowledge of ayurvedic medicine Menorrhagia is identical to conventional targets Treatment: Bleeding control, anaemia prevention and treatment, And restore menstrual pattern, the normal mensuration cycle.

SERIAL			
NO.	HERBAL	BIOLOGICAL NAME OR	TREATMENT OF HEAVY MENSTRUAL
	DRUG	SCIENTIFIC NAME & FAMILY	BLEEDING (REDUCE OFMENORRHAGIA)
1.	Ashoka[²³]	Saraca indica Linn (Leguminosae)	Bleeding hemorrhoids, bleeding ulcers, and for
			hemorrhagic dysentery uterine fibroids. [³³]
2.	Nux –	Strychnos nux vomica Linn	Menses too early, profuse, remove dark colored
	vomica[²³]	(Loganiaceae)	blood, abdomen pain. [³⁴]
3.	Ergot [²³]	<i>Claviceps purpurea</i> (Hyocraceae)	Haemorrhage; puerperal uterus. [³⁵]
5.	2.8001]		
4.	Ginger [²³]	Zingiber officinale (Zingiberaceae)	Dysmenorrhea, control of blood loss; anemia $[^{36,46,47}]$



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429

Volume 8 Issue VII July 2020- Available at www.ijraset.com

5.	Parsley [²⁴]	Petroselium crispum (Apiaceae)	Menstrual problems, UT Infections. [^{38,39}]
6.	Cinnamon tea [²³]	Cinnamomum cassia (Lauraceae)	Reduce crushing menstrual cramps. [³⁷]
7.	Papaya [²³]	Carica papaya (Caricaceae)	Reduce or lighten periods. [40]
8.	Sesame oil [²³]	Sesamum indicum (Pedaliaceae)	Oligomenorrhea. [⁴¹]
9.	Marigold [²⁶]	Tagetes erecta (Asteraceae)	Cervical infections, evaluation of pelvis organs (uterus ,ovaries) [⁴²]
10.	Amla [²³]	Emblica officinalis (Euphorbiaceae)	Control of blood loss; anemia. [42]
11.	Gooseberry [²⁷]	Ribes uva-crispa (Grossurlariaceae)	Hormonal imbalance, uncontrolled bleeding. [44]
12.	Mustard seed [²³]	<i>Brassica juncea</i> L.Czern [indian](Cruciferae)	Excessive bleeding, [⁴⁸]
13.	Banana flower [³²]	Musa acuminate, etc (Musaceae)	Increase progesterone and help control bleeding.
14.	Liquorice [²⁵]	<i>Glycyrrhiza glabra</i> Linn. (leguminosae)	Arresting excessive blood flowin periods. [²⁵]
15.	Mango bark [²⁸]	Mangifera indica (Anacardiaceae)	Arresting excessive periods. [^{43,28}]
16.	Jujube tea [²⁹]	Ziziphus mauritiana (Rhamnaceae)	Stopping excessive menstrual bleeding. [²⁹]
17.	Hemp [³²]	Cannabis sativa Linn.(Cannabaceae)	Reduce crusing menstrual cramps. [49]
18.	Rough chaff[³¹]	Achyranthes aspera (Amaranthaceae)	Stoping heavy bleeding in periods. [48]
19.	Hawthorn ³⁰]	Rhaphiolepis indica (Rosaceae)	Abdominal pain, discharge blood clots, arresting excessive flow. [⁴⁸]
20.	Tenner's cassia [³²]	Senna auriculata (Fabaceae)	Regulating the menstrual cycle ,controlling excessive flow [⁴⁸]
21.	Figs [³²]	Ficus carica (Moraceae)	Menstrual disorders, abdominal pain. [45]

IX. SURGICAL TREATMENT

Surgical treatment may be necessary where there is pelvic pathology as a cause of heavy menstrual bleeding, such as Review polyps or endometriotic masses, but these procedures are not specifically covered in this review. Surgery is also indicated when medical treatment is not tolerated, ineffective or when it is the patient's choice. There are two main types of surgery used in the management of menorrhagia, namely hysterectomy and endometrial ablation.

A. Hysteroscopy

Hysteroscopy removal of sub mucous myomas and polyps, Removing a sub mucous myoma through resection produces a satisfactory result for 70 90 percent of patients. [⁵⁹] 20 30 per cent of these patients must undergo another operation within 3 years. A large uterus, a high number of myomas, and a disadvantageous myoma location in the myometry (over 50%) are factors that increase the need for reoperation. [⁶⁰] More than 10 per cent of all women who are premenopausal have asymptomatic polyps. [⁶⁵] Small polyps can sly spontaneously disappear. Within 3 years of diagnosis, only 10 percent of polyps cause symptoms. [⁶¹] Some 80% of women with severe menstrual bleeding benefit from polyp removal to some extent. The probability of cancer is 0.5 percent in removed polyps. [⁶²] Of all hysteroscopy interventions. Bleeding, uterine perforation and adnexal damage, and liquid medium absorption and retention in the body are the most common. Infections occur in patients in 0.6 1.3 per cent. As a late complication, hematometra may follow. The possibility of normal pregnancy is preserved after myoma resection and polyp removal. It can be considered embolization or open removal of voluminous myomas. [^{63,64,66}].



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429 Volume 8 Issue VII July 2020- Available at www.ijraset.com

B. Endometrial Ablation

This treatment destroys or removes most of the lining of your womb (endometrium). It works to reduce your heavy menstrual bleeding or in many cases it actually causes you to stop having any more periods. [67]

This operation is usually done as day surgery. A small instrument is passed into your womb via your vagina. The aim is to remove as much of the lining of your womb as possible. Endometrial ablation operations vary by the method used to destroy or remove the lining of your womb. The different methods available include:

- 1) *Microwave:* In this method, a slender wand that emits microwaves is placed into your womb, which works to increase the temperature of the lining of your womb to destroy it.
- 2) *Extreme Cold:* This is also called cryoablation and this method uses extreme cold to create two or three ice balls that freeze and destroy the lining of your womb.
- 3) Bipolar Radiofrequency: The instrument that is placed into your womb puts out short waves of energy that destroy the lining of your womb.
- 4) *Electrosurgery:* This method uses heat to destroy the lining of your womb. A small instrument which can be a roller ball or a wire loop becomes hot. It is then used to carve grooves into the lining of your womb.
- 5) *Heated Balloon:* A balloon device is inserted through the neck of your womb and then inflated with fluid which is heated.

Although endometrial ablation prevents women from having children in the future, it cannot actually be relied on as contraception. This is because there have been some cases of women becoming pregnant after this operation.

Endometrial ablation is not usually recommended if you have large fibroids or if you want to have children in the future, as it can affect your fertility. It can be an option if you have small fibroids however. Following this type of surgery, you may have some discomfort in your lower tummy (abdomen), which is usually eased by taking painkillers. You will need to wear a sanitary towel for a few days after the operation, as it is common to have some vaginal bleeding. You will usually be able to go home on the same day when you feel ready. Most women are able to return to most normal activities in 3-5 days. Having sex (intercourse) and doing very strenuous activities should be avoided for around two weeks following this type of surgery. It is normal to have an increased vaginal discharge for 2-4 weeks after the operation. You should avoid using tampons for at least one month after having an endometrial ablation, to help reduce your risk of infection. If you develop any prolonged vaginal bleeding, offensive smelling discharge, severe pain or a high temperature (fever), you should contact your doctor as soon as possible. These symptoms may be due to an infection, which can be treated with antibiotics. [⁶⁸]

C. Combination Therapies

Insufficient evidence exists on the effectiveness of mixed therapies. Since drug therapies have various mechanisms of Action, different drugs may be used in combination, if Does not achieve sufficient effect with 1 drug. Because oral contraceptives, or hormonal IUS for example canbe combined with either, tranexamic acid or anti-inflammatory acid Drogues. can be used in combination with hormonal IUS with destruction of the endometrial. It can just be inserted upon or after the procedure, if necessary. $[^{69}]$

D. Dilatation and Curettage (D&C)

A procedure in which the uterus lining upper layer is removed to reduce menstrual bleeding. Over time this procedure could need to be repeated. Menorrhagia is prevalent among women. But, a lot of women don't know they can get any help. Others don't get help because they're too embarrassed to discuss their issue with a doctor. It's very important to talk openly with your doctor to make sure you're diagnosed correctly and get the right treatment. [⁶⁹]

X. CONCLUSIONS

Menorrhagia is a disorder which could adversely affect women's quality of life. The both primary care and gynecological departments with effective therapies this can be resolved in the initial stages investigated. [⁷⁰] The management should aim to reduce menstrual flow , improve quality of life and reduce the likelihood of iron deficiency anemia once another pathology has been excluded. However, they should investigate the definite cause of menorrhagia. Women with menorrhagia should be given proper care along with medical interventions, herbal treatment and surgical treatment. [⁷¹] Treatment for complications should be provided at the initial stages. Intrauterine device has been found to be acceptable as it has shown more adherences and therefore it is considered the first line of menorrhagia treatment. Combined oral contraceptive pills and tranexamicacid were discovered as second line therapy choice.



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429 Volume 8 Issue VII July 2020- Available at www.ijraset.com

That the in counseling women regarding investigation and clinical history and treatment options for their menorrhagia (heavy menstrual bleeding); risks and benefits for each treatment discussed with patients, to allow women to be a positions to that their preferences. $[^{72}]$

Future research should focus on qualitative research to understand patient's experience with menorrhagia, which will be better for effectiveness of the care and treatment provided.

REFERENCES

- G.Lefebvre, G.R.Graves and G.A. Vilos, "Guidelines for the management of abnormal uterine bleeding. SOGC clinical practice guidelines," Journal of Obstetrics and Gynaecology2001; 106:1-6.
- R. Rose, A. I. Bril J. L. Engstrom, K. M. Polhill, L. Fritzb and C. M. Lukanich, "Midwifery care of the woman with menorrhagia," Journal of Nurse-midwifery 1999;44:89-105.
- [3] S. Von Mackensen and M. A. Clark, "The impact of menstrual disorders on quality of life in normal women with inherited bleeding disorders," Haemophilia 2010; 16(6):832-839.
- [4] M. A. Clark and A. A. Matteson, "Questioning our questions: do frequently asked questions adequately cover the aspects of women's lives affected by abnormal uterine bleeding opinions of women and participating in group discussions," Women and health 2010;50(2):195-211.
- [5] Iyer V, Jepson, R Farquhar C. Oral contraceptive pills for heavy menstrual bleeding, The Cochrane Library, Issue 4(Cochrane Review), 2002.
- [6] Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. The Cochrane Library, Issue 4, 2002. http://www.update-software.com [Accessed 9 November 2003].
- [7] Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol. 1994 Jul. 101 Supply, 11:15-8. [Medline].
- [8] Apgar, B., Kaufman, A.H., George-Nwogu, U., & Kittendorf, A. (2007, June 15). Treatment of menorrhagia.
- [9] Oehler MK, Rees MC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003; 82: 405-422.
- [10] Ferri FF. Menorrhagia. In: Ferri's Clinical Advisor 2017. Philadelphia, Pa.: Elsevier; 2017. https://www.clinicalkey.com. Accessed April 10, 2017.
- [11] Heavy menstrual bleeding. Centers for Disease Control and Prevention. https://www.cdc.gov/ncbddd/blooddisorders/women/menorrhagia.html. Accessed April 13, 2017.
- [12] Frequently asked questions. Gynecologic problems FAQ095. Abnormal uterine bleeding. American College of Obstetricians and Gynecologists. http://www.acog.org/Patients/FAQs/Abnormal-Uterine-Bleeding. Accessed April. 13, 2017.
- [13] Cunningham FG, et al. abnormal uterine bleeding. In: Williams Obstetrics. 24th ed. New York, N.Y.: The McGraw-Hill Companies; 2014. http://accessmedicine.mhmedical.com. Accessed April 10, 2017.
- [14] Kaunitz AM. Approach to abnormal uterine bleeding in nonpregnant reproductive-age women. https://www.uptodate.com/home. Accessed April 13, 2017.
- [15] Lethaby A, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding. The Cochrane Library, Issue 4, 2002. http://www.update-software.com [Accessed 9 November 2003].
- [16] Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. The Cochrane Library, Issue 1, 2003. http://www.update-software.com [Accessed 9 November 2003].
- [17] Lethaby A, Cooke I, Rees M. Progesterone/progestogen releasing intrauterine systems for heavy menstrual bleeding. The Cochrane Library, Issue 4, 2003. http://www.update-software.com [Accessed 9 November 2003].
- [18] Kaunitz AM. Management of abnormal uterine bleeding. https://www.uptodate.com/home. Accessed April 13, 2017.
- [19] Dijkhuizen FP, Mol BW, Brolmann HA, Heintz AP. The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis. Cancer. 2000 Oct 15. 89(8):1765-72. [Medline].
- [20] Shaw RW. Assessment of medical treatments for menorrhagia. Br J Obstet Gynaecol. 1994 Jul. 101 Supply, 11:15-8. [Medline].
- [21] Santer M, Warner P, Wyke S. (2005) 'A Scottish postal survey suggested that the prevailing clinical preoccupation with heavy periods does not reflect the epidemiology of reported symptoms and problems', Journal of Clinical Epidemiology, 58:1206
- [22] Santoro N, Brown JR, Adel T, Skurnick JH. (1996) 'Characterization of reproductive hormonal dynamics in the perimenopause', The Journal of Clinical Endocrinology and Metabolism, 81:1495.
- [23] Dr. C.K. Kokate, A. P. Purohit, S. B. Gokhale; 'Pharmacognosy' Nirali Prakashan , fouty nineth edition , January 2014;N1275.
- [24] The Euro+Med Plantbase Project: Petroselinum crispum Archived 2012-03-09 at the Wayback Machine licorice.
- [25] Dr.jvhebbar (ayu) licorice-benefits-medicinal-qualities-complete-ayurveda-details/text=Licorice 20benefits2012/12/08.
- [26] Genus: tagetes L. germplasm resource information network. United States department of agriculture.2011-01-06. Archived from the original on 2012-03-09. Retrived 2011-07-14.
- [27] Doronina, A.Ju. & Terekhina, N.V. (2003–2009). "Ribes uva-crispa L. European gooseberry". AgroAtlas Interactive Agricultural Ecological Atlas of Russia and Neighboring Countries. Retrieved 3 December 2017.
- [28] World conservation monitoring Centre (1998). Magnifera indica. The ICUN Red list of threatened species 1998.
- [29] : Morton, J. (1987). "Indian Jujube. p. 272–275. In: Fruits of warm climates. Julia F. Morton, Miami, FL". Department of Horticulture and Landscape Architecture at Purdue University. Retrieved 2016-01-29.
- [30] Indian Hawthorn Care Guide: Growing Information and Tips For Rhaphiolepis umbellate
- [31] 1771 illustration from Trew, C.J., Plantae selectee quarum imagines ad exemplaria naturalia Londoni, in hortis curiosrum nutrit, vol.8: t73(1771)
- [32] Nardi, Isabella (2007). The Theory of Citrasutras in Indian Painting. Routledge. p. 121.
- [33] Subhuti Dharmananda, Ph.D., Director, Institute for Traditional Medicine, Portland, Oregon; excessive uterine bleeding treated with saraca, an ayurvedic herb; September 2004.
- [34] Dr. Manisha Bhatia; Menorrhagia, Excessive Bleeding During Menses, August 31, 2015.
- [35] W, J. Garrett, M.B., D.Phil., F.R. C.S, E., M, R.C.O.G. and J. Chasser Moir, M.A., M.D., F. R. C. S. E., F.R.C.O.G., Hon.LL.D. Nuffield Department of obstetrics and gynecology, university of oxford; ergot and the non-pregnant uterus; 1958.



ISSN: 2321-9653; IC Value: 45.98; SJ Impact Factor: 7.429

Volume 8 Issue VII July 2020- Available at www.ijraset.com

- [36] Chuang CH, Doyle P, Wang JD, et al. Herbal medicines used during the first trimester and major congenital malformations: an analysis of data from a pregnancy cohort study. Drug Saf 2006; 29:537-48.
- [37] Ciganda C and Laborde A. Herbal infusions used for induced abortion. J Toxicol. Clin Toxicol. 2003; 41:235-239.
- [38] Kashefi F, Khajehei M, Alavinia, et al. Effect of ginger on heavy menstrual bleeding: a placebo-controlled randomized clinical trial. Phytotherapy Research. 2015; 29:114-119.
- [39] Daily JW, Zhang X, Kim DS, Park S. Efficacy of ginger for alleviating the symptoms of primary dysmenorrhea: A systematic review and meta-analysis of randomized clinical trials. Pain Med. 2015; 16(2):2243-55.
- [40] Yang H, Zhou B, Prinz M, Siegel D. Proteomic analysis of menstrual blood. Mol Cell Proteomics. 2012; 11(10):1024–1035. doi:10.1074/mcp.M112.01839.
- [41] Devoto E, Aravena L, Gaete X. [Has oligomenorrhea a pathological meaning? The importance of this symptom in internal medicine]. Rev Med Chil. 1998; 126(8): 943 -51 [PubMed]
- [42] Dr. Minaskshi chauhan ; herbal remidies for menorrhagia (heavy menstrual bleeding) https://www.planetayurveda.com/library/menorrhagia/
- [43] Dr. MS Krishnamurty and Dr. Hebbar; heavy-periods-menstrual-bleeding-irregular-periods-ayurvedic-herbal-remedy; 09/09/2009. https://www.easyayurveda.com/
- [44] Vinnet Bhatangar, general health ;How-can-we-reduce-high-menstrual-flow-and-abdomen-pain 2016. https://www.quora.com.
- [45] Anupama; Cluster fig; Daily life experience of Health, Ayurveda, Medicines, complementary therapies; 2014.
- [46] Kashefi F, Khajehei M, Alavinia, et al. Effect of ginger on heavy menstrual bleeding: a placebo-controlled randomized clinical trial. Phytotherapy Research. 2015; 29:114-119.
- [47] Daily JW, Zhang X, Kim DS, Park S. Efficacy of ginger for alleviating the symptoms of primary dysmenorrhea: A systematic review and meta-analysis of randomized clinical trials. Pain Med. 2015; 16(2):2243-55.
- [48] Jurema M, Zacur H. Menorrhagia. UpToDate. Available at http://bit.ly/fHJVtw. Accessed: March 29, 2009.
- [49] Fraser IS McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia. Aust N Z J Obstet Gynaecol. 1991 Feb. 31(1):66-70. [Medline].
- [50] Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011 Apr. 117(4):777-87. [Medline].
- [51] Andersson JK, Rybo G. Levonorgestrel-releasing intrauterine device in the treatment of menorrhagia. Br J Obstet Gynaecol. 1990 Aug. 97(8):690-4. [Medline].
- [52] Rauramo I, Elo I, Istre O. Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resection. Obstet Gynecol. 2004 Dec. 104(6):1314-21. [Medline].
- [53] FDA approves intrauterine device for heavy menstrual bleeding. PR Newswire. Available at http://bit.ly/eKOVjr. 2009 Oct 01; Accessed: October 5, 2009.
- [54] Kaunitz AM, Bissonnette F, Monteiro I, Lukkari-Lax E, Muysers C, Jensen JT. Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Sep. 116(3):625-32. [Medline].
- [55] Kim JY, No JH, Kim K, et al. Effect of myoma size on failure of thermal balloon ablation or levonorgestrel releasing intrauterine system treatment in women with menorrhagia. Obstet Gynecol Sci. 2013 Jan. 56(1):36-40. [Medline]. [Full Text].
- [56] Gupta JK, Daniels JP, Middleton LJ, et al. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. Health Technol Assess. 2015 Oct. 19 (88):1-118. [Medline].
- [57] Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized controlled trial. Obstet Gynecol. 2010 Oct. 116(4):865-75. [Medline].
- [58] Ray S, Ray A. Non-surgical interventions for treating heavy menstrual bleeding (menorrhagia) in women with bleeding disorders. Cochrane Database Syst Rev. 2016 Nov 10. 11:CD010338. [Medline].
- [59] Fernandez H, Kadoch O, Capella-Allouc S, Gervaise A, Taylor S, Frydman R. Hysteroscopic resection of submucous myomas: long term results. French Ann Chir. 2001; /126:/58 64.
- [60] Vercellini P, Zaina B, Yaylayan L, Pisacreta A, De Giorgi O, Crosignani PG. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol. 1999; /94:/341 7.
- [61] Emanuel MH, Wamsteker K, Hart AA, Metz G, Lammes FB. Long-term results of hysteroscopic myomectomy for abnormal uterine bleeding. Obstet Gynecol. 1999;/93:/743 8.
- [62] Hart R, Molna'r BG, Magos A. Long term follow up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol. 1999; /106:/700_5.
- [63] 50 DeWaay DJ, Syrop CH, Nygaard I, Davis WA, Van Voorhis BJ. Natural history of uterine polyps and leiomyomata. Obstet Gynecol. 2002; /100:/37.
- [64] 56 Phillips DR, Nathanson HG, Meltzer SM, Milim SJ, Haselkorn JS, Johnson P. Transcervical electrosurgical resection of submucous leiomyomas for chronic menorrhagia. J Am Assoc Gynecol Laparosc. 1995; 2:147 53; erratum in: J Am Assoc Gynecol Laparosc. 1995; 2:496.
- [65] 72 Brooks PG, Loffer FD, Serden SP. Resectoscopic removal of symptomatic intrauterine lesions. J Reprod Med. 1989; /34:/435 7.
- [66] Indman PD. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol. 1993;/81:/716 20.
- [67] Nakamura K, Nakayama K, Ishikawa M, et al. Efficacy of multiple microwave endometrial ablation technique for menorrhagia resulting from adenomyosis. J Obstet Gynaecol Res. 2015 Nov. 41 (11):1769-72. [Medline].
- [68] Lethaby A, Hickey M, Garry R, Penninx J. Endometrial resection / ablation techniques for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009 Oct 7. CD001501. [Medline].
- [69] Ref. Women with Inherited Bleeding Disorders: Surgical Options for Menorrhagia. Canadian Hemophilia Society. http://www.hemophilia.caExternal.
- [70] Royal College of Obstetricians and Gynaecologists (RCOG). The Initial Management of Menorrhagia. London, UK: RCOG, 1998
- [71] Effective Health Care. The management of menorrhagia. Effective Health Care Bulletin 1995; 9: 1–14.
- [72] Coulter A, Peto V, Doll H. Patients' preferences and general practitioners' decisions in the treatment of menstrual.











45.98



IMPACT FACTOR: 7.129







INTERNATIONAL JOURNAL FOR RESEARCH

IN APPLIED SCIENCE & ENGINEERING TECHNOLOGY

Call : 08813907089 🕓 (24*7 Support on Whatsapp)